Sharlene Adams

2.4k citations

44 papers · 2.0k indexed · 1 hit paper · h-index 16

Immunology top 2%
Oncology top 5%
Radiology, Nuclear Medicine and Imaging top 2%
Molecular Biology
Rheumatology top 2%

Co-authors: Somnath Datta Chandra Mohan Barry Jones Glenn T. Miller Michael I. Jesson Barbara Wallner Takeshi Watanabe Robert E. Humphreys
Topics: Monoclonal and Polyclonal Antibodies Research (21 papers)HER2/EGFR in Cancer Research (10 papers)Glycosylation and Glycoproteins Research (6 papers)
Cited by: Immunology Rheumatology Radiology, Nuclear Medicine and Imaging
Journals: Proceedings of the National Academy of Sciences The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: United States Australia Japan

In The Last Decade

Sharlene Adams

44 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus.

1993 527 citations Chandra Mohan, Sharlene Adams et al. The Journal of Experimental Medicine profile →

Peers

Countries citing papers authored by Sharlene Adams

Since Specialization

Citations

This map shows the geographic impact of Sharlene Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharlene Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharlene Adams more than expected).

Fields of papers citing papers by Sharlene Adams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharlene Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharlene Adams. The network helps show where Sharlene Adams may publish in the future.

Co-authorship network of co-authors of Sharlene Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Sharlene Adams. A scholar is included among the top collaborators of Sharlene Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharlene Adams. Sharlene Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer 2018 ·Clinical Cancer Research ·(unknown),Emily A. Pace,Sharlene Adams,Michael D. Curley,Victoria Rimkunas,Lin Nie,(unknown),Troy Bloom,Sergio Iadevaia,Jason Baum,(unknown),Akos Czibere,Chrystal U. Louis,Daryl C. Drummond,Ulrik B. Nielsen,Birgit Schoeberl,J. Marc Pipas,Robert M. Straubinger,Vasileios Askoxylakis,Alexey A. Lugovskoy	44
2	A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells 2018 ·Blood Advances ·Yelena Kovtun,Gregory E. Jones,Sharlene Adams,Lauren Harvey,Charlene A. Audette,Alan Wilhelm,Chen Bai,Lingyun Rui,Rassol Laleau,(unknown),Olga Ab,Yulius Y. Setiady,Nicholas C. Yoder,Victor S. Goldmacher,Ravi Chari,Jan Pinkas,Thomas Chittenden	129
3	Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models 2018 ·Blood ·(unknown),(unknown),Julie A. Adams,(unknown),(unknown),(unknown),Callum M. Sloss,(unknown),Yelena Kovtun,Sharlene Adams,Eunice S. Wang	3
4	IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo 2017 ·Blood ·Sharlene Adams,Meghan Kelly,(unknown),Alan Wilhelm,(unknown),Leanne Lanieri,Callum M. Sloss,Angela Romanelli	6
5	MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors 2013 ·Molecular Cancer Therapeutics ·Jonathan B. Fitzgerald,Bryan W. Johnson,Jason Baum,Sharlene Adams,Sergio Iadevaia,Jian Tang,Victoria Rimkunas,Lihui Xu,Neeraj Kohli,Rachel Rennard,(unknown),Yang Jiao,Brian D. Harms,Kenneth J. Olivier,Birgit Schoeberl,Ulrik B. Nielsen,Alexey A. Lugovskoy	87
6	Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 2012 ·Molecular Cancer Therapeutics ·Charlotte F. McDonagh,Alexandra Huhalov,Brian D. Harms,Sharlene Adams,Violette Paragas,(unknown),Bo Zhang,Lia Luus,Ryan Overland,Stephanie A. Nguyen,Jinming Gu,Neeraj Kohli,(unknown),Michael J. Feldhaus,Arthur J. Kudla,Birgit Schoeberl,Ulrik B. Nielsen	222
7	Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity 2012 ·Cancer Research ·Jason Baum,Bryan W. Johnson,Sharlene Adams,Jian Tang,Neeraj Kohli,Rachel Rennard,(unknown),Lihui Xu,Yang Jiao,Birgit Schoeberl,Ulrik B. Nielsen,Jonathan B. Fitzgerald,Alexey A. Lugovskoy	3
8	Immune mechanism of action of talabostat: a dipeptidyl peptidase targeted antitumor agent 2007 ·Cancer Research ·Michael I. Jesson,Paul A. McLean,Glenn T. Miller,Sharlene Adams,Justin Aubin,Barry Jones	6
9	Characterization of innate effector cells involved in the anti-tumor activity of talabostat (PT-100) 2006 ·Cancer Research ·Barry Jones,Sharlene Adams	3
10	Enhanced anti-tumor activity of dipeptidyl peptidase inhibitor PT-100 in combination with chemotherapy in mice. 2004 ·Cancer Research ·Sharlene Adams,Barry Jones	1
11	Perianal Hodgkin's lymphoma complicating Crohn's disease 2003 ·International Journal of Colorectal Disease ·(unknown),Sharlene Adams,Mark E. Smith,Kenneth B. Hosie	6
12	Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide 2000 ·Vaccine ·Robert E. Humphreys,Sharlene Adams,(unknown),(unknown),Eric von Hofe,Minzhen Xu	60
13	Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. 1997 ·PubMed ·Sharlene Adams,Fernando Alberício,Jordi Alsina,Edwin R. Smith,Robert E. Humphreys	21
14	Invriant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules 1995 ·European Journal of Immunology ·Sharlene Adams,Robert E. Humphreys	38
15	Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus.breakdown → 1993 ·The Journal of Experimental Medicine ·Chandra Mohan,Sharlene Adams,(unknown),Somnath Datta	527
16	Comparison of actual and random-positioning-model distributions of peptide scavenging and T cell-presented sites in antigenic proteins 1993 ·Vaccine ·Michael Salomon,Sharlene Adams,Animesh Pardanani,(unknown),Robert E. Humphreys,(unknown)	1
17	Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites 1992 ·Kidney International ·Demetrios Vlahakos,Mary H. Foster,Sharlene Adams,Michael Katz,Angelo A. Ucci,K J Barrett,Syamal K. Datta,Michael P. Madaio	170
18	Junctional region sequences of T-cell receptor beta-chain genes expressed by pathogenic anti-DNA autoantibody-inducing helper T cells from lupus mice: possible selection by cationic autoantigens. 1991 ·Proceedings of the National Academy of Sciences ·Sharlene Adams,Pierre Leblanc,Somnath Datta	76
19	T cell receptor V_β genes expressed by IgG anti‐DNA autoantibody‐inducing T cells in lupus nephritis: Forbidden receptors and double‐negative T cells 1990 ·European Journal of Immunology ·Sharlene Adams,(unknown),Krishna B. Sainis,Syamal K. Datta	29
20	Schistosoma mansoni: The basis for the antischistosomal effect of cyclosporine A 1988 ·Experimental Parasitology ·Héctor Pons,Sharlene Adams,Miguel J. Stadecker	9

About Sharlene Adams

Sharlene Adams is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology, having authored 44 papers that have together received 2.0k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (21 papers), HER2/EGFR in Cancer Research (10 papers) and Glycosylation and Glycoproteins Research (6 papers). The work is most often cited by research in Immunology (998 citations), Rheumatology (492 citations) and Radiology, Nuclear Medicine and Imaging (641 citations). Sharlene Adams has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Somnath Datta, Chandra Mohan, Barry Jones, Glenn T. Miller, Michael I. Jesson, Barbara Wallner, Takeshi Watanabe, Robert E. Humphreys, Syamal K. Datta and Pierre Leblanc. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact